Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 17:15:1381712.
doi: 10.3389/fphar.2024.1381712. eCollection 2024.

Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review

Shihao Zheng  1   2 , Chengyuan Xue  1   2 , Size Li  1   2 , Xiaobin Zao  1   3 , Xiaoke Li  1   4 , Qiyao Liu  1   2 , Xu Cao  1   4 , Wei Wang  1   2 , Wenying Qi  1   2 , Peng Zhang  5 , Yongan Ye  1   4
Affiliations
Review

Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review

Shihao Zheng et al. Front Pharmacol. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a clinicopathological syndrome characterized by abnormalities in hepatic fat deposition, the incidence of which has been increasing year by year in recent years. It has become the largest chronic liver disease globally and one of the important causes of cirrhosis and even primary liver cancer formation. The pathogenesis of NAFLD has not yet been fully clarified. Modern medicine lacks targeted clinical treatment protocols for NAFLD, and most drugs lack efficacy and have high side effects. In contrast, Traditional Chinese Medicine (TCM) has significant advantages in the treatment and prevention of NAFLD, which have been widely recognized by scholars around the world. In recent years, through the establishment of a "medicine-disease-target-pathway" network relationship, network pharmacology can explore the molecular basis of the role of medicines in disease prevention and treatment from various perspectives, predicting the pharmacological mechanism of the corresponding medicines. This approach is compatible with the holistic view and treatment based on pattern differentiation of TCM and has been widely used in TCM research. In this paper, by searching relevant databases such as PubMed, Web of Science, and Embase, we reviewed and analyzed the relevant signaling pathways and specific mechanisms of action of single Chinese medicine, Chinese medicine combinations, and Chinese patent medicine for the treatment of NAFLD in recent years. These related studies fully demonstrated the therapeutic characteristics of TCM with multi-components, multi-targets, and multi-pathways, which provided strong support for the exact efficacy of TCM exerted in the clinic. In conclusion, we believe that network pharmacology is more in line with the TCM mindset of treating diseases, but with some limitations. In the future, we should eliminate the potential risks of false positives and false negatives, clarify the interconnectivity between components, targets, and diseases, and conduct deeper clinical or experimental studies.

Keywords: network pharmacology; non-alcoholic fatty liver disease; research progress; review; traditional Chinese medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Disease process of NAFLD.
FIGURE 2
FIGURE 2
NAFLD and network pharmacology.
FIGURE 3
FIGURE 3
Flowchart of network pharmacology.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abenavoli L., Izzo A. A., Milić N., Cicala C., Santini A., Capasso R. (2018). Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother. Res. 32 (11), 2202–2213. 10.1002/ptr.6171 - DOI - PubMed
    1. Adams L. A., Lymp J. F., St Sauver J., Sanderson S. O., Lindor K. D., Feldstein A., et al. (2005). The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (1), 113–121. 10.1053/j.gastro.2005.04.014 - DOI - PubMed
    1. Ashburner M., Ball C. A., Blake J. A., Botstein D., Butler H., Cherry J. M., et al. (2000). Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25 (1), 25–29. 10.1038/75556 - DOI - PMC - PubMed
    1. Barbarino J. M., Whirl-Carrillo M., Altman R. B., Klein T. E. (2018). PharmGKB: a worldwide resource for pharmacogenomic information. Wiley Interdiscip. Rev. Syst. Biol. Med. 10 (4), e1417. 10.1002/wsbm.1417 - DOI - PMC - PubMed
    1. Başaranoğlu M., Örmeci N. (2014). Nonalcoholic fatty liver disease: diagnosis, pathogenesis, and management. Turk J. Gastroenterol. 25 (2), 127–132. 10.5152/tjg.2014.7675 - DOI - PubMed

LinkOut - more resources